iRadimed Q2 2024 Adj. EPS $0.42 Beats $0.36 Estimate, Sales $17.929M Beat $17.649M Estimate
Portfolio Pulse from Benzinga Newsdesk
iRadimed (NASDAQ:IRMD) reported Q2 2024 adjusted EPS of $0.42, beating the $0.36 estimate by 16.67%. Sales were $17.929M, surpassing the $17.649M estimate and marking an 11.15% increase from the same period last year.
August 01, 2024 | 12:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
iRadimed reported strong Q2 2024 results with EPS of $0.42 beating estimates by 16.67% and sales of $17.929M surpassing estimates by 1.59%. This indicates robust financial performance and growth.
The strong earnings and sales performance exceeding analyst estimates suggest positive investor sentiment and potential short-term stock price appreciation for iRadimed.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100